|
⚲
|
| Keyboard |
| NQ Hcif GP Ltd | |
|---|---|
| Firm | NovaQuest Capital Management LLC |
| Address | c/o NovaQuest Capital Management, LLC 4208 Six Forks Road, Suite 920 Raleigh, NC 27609 |
| Source |
| Associated Funds | Form D | Role | 2011 - 2026 | Raised | AUM |
|---|---|---|---|---|---|
| NovaQuest Capital Management LLC | |||||
| NovaQuest Co-Investment Fund I LP | 021-195929 | Executive Officer | 80.0 M | 194.8 M | |
| NovaQuest Pharma Opportunities Fund III LP | 021-150993 | Executive Officer | 426.1 M of 500.0 M |
48.1 M | |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Revance Therapeutics Inc RVNC
Stock Option (Right to Buy) · derivative
|
2015-05-07 | Other | 8,000 | $0.00 | |
|
Revance Therapeutics Inc RVNC
Stock Option (Right to Buy) · derivative
|
2015-05-07 | Other | 8,000 | $0.00 | |
|
Revance Therapeutics Inc RVNC
Stock Option (Right to Buy) · derivative
|
2014-04-08 | Other | 8,000 | $0.00 | |
|
Revance Therapeutics Inc RVNC
Stock Option (Right to Buy) · derivative
|
2014-04-08 | Other | 8,000 | $0.00 | |
|
Revance Therapeutics Inc RVNC
Series E-5 Convertible Preferred Stock · derivative
|
2014-02-11 | Conversion | 500,039 | ||
|
Revance Therapeutics Inc RVNC
Common Stock
|
2014-02-11 | Conversion | 2,039,382 | ||
|
Revance Therapeutics Inc RVNC
Warrant to Purchase Common Stock · derivative
|
2014-02-11 | Option exercise | 398,717 | ||
|
Revance Therapeutics Inc RVNC
Series E-4 Convertible Preferred Stock · derivative
|
2014-02-11 | Conversion | 1,539,343 | ||
|
Revance Therapeutics Inc RVNC
Common Stock
|
2014-02-11 | Option exercise | 398,717 | ||
|
Revance Therapeutics Inc RVNC
Common Stock
|
2014-02-11 | Conversion | 658,551 | ||
|
Revance Therapeutics Inc RVNC
Convertible Promissory Notes · derivative
|
2014-02-11 | Conversion | 658,551 |